Evidence & regulatory context
- Mechanism
- Neutralising antibody against thrombopoietin, blocking MPL (c-Mpl) receptor signalling and megakaryopoiesis; used as a loss-of-function intervention. No ChEMBL drug entity and no registered human trials of a TPO-neutralising antibody. Registered human agents act in the opposite direction (recombinant human TPO, romiplostim and other TPO receptor agonists).
- Target
- Not recorded
- Injury models
- Chemical/toxin
- Reported indication
- Not recorded
- First approval
- Not recorded
- Development stage
- Not recorded
- ChEMBL record
- Not recorded
- ChEMBL max phase
- Not recorded
- Synonyms
- Anti-TPO antibody; Anti-thrombopoietin neutralising antibody
- Note
- Not recorded
Clinical trials 0
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
No linked human trial in this dataset.
Preclinical evidence 1
1 studies reported at therapy level; 1 evidence entries itemised.
MouseChemical/toxinC57BL/6Male
Model: L-arginine induced acute necrotising pancreatitis
Serum thrombopoietin was raised in necrotising pancreatitis. Thrombopoietin administration worsened acinar necrosis and pancreatitis associated lung injury, whereas anti-thrombopoietin antibody reduced acinar necrosis and attenuated lung injury, with effects on acinar regeneration and apoptosis.
Extraction: extract · Supplied extraction confidence: 0.65. Machine-extracted fields require source verification.
